Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?

about

Should expectations about the rate of new antiretroviral drug development impact the timing of HIV treatment initiation and expectations about treatment benefits?Cardiovascular disease and HIV infection.Creating impact with operations research in health: making room for practice in academia.

P2860

Q28539995-E033D6A1-D420-49DD-A206-09B65425528D Q37661603-8F43E12E-DA32-46C6-8086-E3903AE98F1D Q45200257-1A863CC6-C2DE-42B7-AE9F-6B1B87FD5C68

P2860

Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?

Item

http://www.wikidata.org/entity/Q36338387

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Balancing immunological benefi ...... s immediate treatment optimal?

@ast

Balancing immunological benefi ...... s immediate treatment optimal?

@en

type

Item

label

Balancing immunological benefi ...... s immediate treatment optimal?

@ast

Balancing immunological benefi ...... s immediate treatment optimal?

@en

prefLabel

Balancing immunological benefi ...... s immediate treatment optimal?

@ast

Balancing immunological benefi ...... s immediate treatment optimal?

@en

P1476

Balancing immunological benefi ...... s immediate treatment optimal?

@en

P2093

Diana M Negoescu

http://www.w3.org/2001/XMLSchema#string

Douglas K Owens

http://www.w3.org/2001/XMLSchema#string

Eran Bendavid

http://www.w3.org/2001/XMLSchema#string

Margaret L Brandeau

http://www.w3.org/2001/XMLSchema#string

P2860

Estimated HIV incidence in the United States, 2006-2009

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

CD4+ count-guided interruption of antiretroviral treatment

Deaths: final data for 2006.

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Effect of early versus deferred antiretroviral therapy for HIV on survival.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

Hit HIV-1 hard, but only when necessary.

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

P304

1392-1399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIS731

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230784070

http://www.w3.org/2001/XMLSchema#string

P698

22942203

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3478144

http://www.w3.org/2001/XMLSchema#string

Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?

about

P2860

P2860

Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932